Inside This Issue: Neuropathic Pain
Top News Alerts: Product Updates, Deals & Financings
Conference Highlights: AntiEpileptic Drug and Device Trials Conference
Company Spotlight: Stimwave Technologies
Subscribe now to access over 50 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: AAN Brings Flurry of Multiple Sclerosis Data and Trading
A number of companies revealed data on their oral multiple sclerosis treatments in development at the American Academy of Neurology annual meeting in Honolulu. Biogen Idec (BIIB) announced better than expected results from the first of two pivotal trials of their immune modulator BG-12. Information from the meeting and later in their quarterly report revealed that twice daily oral BG-12 reduced annualized relapse rate by 53% and disability progression by 38% compared to placebo at two years. A previous 6 month trial had put the reduction in relapse rate at 32%, similar to mainstay “ABCR” therapies....
Pursuing Relief and Revenues in Neuropathic Pain
Neuropathic pain is a large and very active market that has surpassed $5 billion in annual sales. So far, though, there has been no clear winner, in part because of an underlying heterogeneity in pathogenesis of the syndromes typically clustered under this heading. Another factor is that most of the current treatment options provide relatively modest pain relief, hovering around 30-50%, and even those numbers are only reached in less than half the patients. As a result, a large market remains for new drugs, surgical approaches and increasingly for implantable devices such as pain pumps and neurostimulators. This article outlines current treatment in development for neuropathic pain...
Stimwave Technologies: Smaller, Cheaper, Faster
Neural Micro LLC is a new incubator developing wirelessly powered, injectable neurostimulators leveraging nanotechnology. The first spinout, Stimwave Technologies, is focused on various types of pain management systems, including chronic low back and leg pain, peripheral pain, myalgias and migraines. NeuroInsights spoke with founder and Executive Director Laura Tyler Perryman about the new company...
Companies Covered In This Issue Include: Pfizer, Intellipharmaceuticals, Avanir, Biodelivery, BioTie Therapies, Covidien, Neuros Medical, CvRx, GSK, Xenoport, Johnson & Johnson, StemCells, Medivation, Pfizer, Eisai, Edge Therapeutics, Neurovasx, Sonova, Advanced Bionics, Neuronetics, EmSense, Neurotech, Boehringer Ingelheim, Novartis, Regeneron Pharmaceuticals, Prana Biotechnology, Anavex Life Sciences, Second Sight, Noscira, Eisai, Teikoku Pharma, Xenoport, Pain Therapeutics, QRxPharma, Shire, Newron Pharma, Merck Serono, SMT Research and Development, Quest Diagnostics, Athena Diagnostics, Checkpoint Surgical, To-BBB, Aldagen, Sangamo Biosciences, CHDI Foundation, Envoy Medical, Cleveland Medical Devices, Great Lakes NeuroTech, Oraya Therapeutics, Brainlab, Surgivision, Sonitus Medical, Brainsway, NFocus Neuromedical, Symbios Holdings, Link Medicine, BlueBird, Posit Science, Rules-Based Medicine, GE Healthcare, Proteostasis Therapeutics, Eli Lilly, Medtronic, SPR Therapeutics, and Intrapace
Subscribe Now:
|
